Yahoo Movies
Kyle Lowry on NBA going forward with All-Star Game
Fresh off scoring 30 points in a win versus Brooklyn, Toronto Raptors point guard Kyle Lowry explains the pros and cons of the NBA doing an All-Star Game in Atlanta during the pandemic.
Fresh off scoring 30 points in a win versus Brooklyn, Toronto Raptors point guard Kyle Lowry explains the pros and cons of the NBA doing an All-Star Game in Atlanta during the pandemic.
The U.S. trade deficit rose 1.9% in January as the coronavirus pandemic continued to disrupt global commerce. The gap between the goods and services the United States sold and what it bought abroad rose to $68.2 billion from $67 billion in December, the Commerce Department reported Friday. The trade deficit with Mexico rose $1.6 billion to $11.9 billion in January.
Shoppers say "you really can't go wrong" with this on-sale machine.
Ford senior leaders will discuss the company’s European business and roadmap for sustained profitability with Jefferies lead auto analyst Philippe Houchois during the Exane BNP Paribas & Jefferies Geneva Motor Show Conference on Wednesday, March 10, at 8 a.m. ET.
The Duchess of Cambridge has also worn a very similar style.
Veteran finance exec Drew Vollero, who shepherded Snapchat parent Snap’s initial public offering in 2017, has joined Reddit as its first CFO — as the internet discussion site is mulling an IPO of its own. Vollero, who has 30-plus years of industry experience including a 15-year stint at Mattel, will assume leadership of Reddit’s finance […]
The "Robotic Waste Sorting System Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
OVERLAND PARK, Kan., March 05, 2021 (GLOBE NEWSWIRE) -- Yellow Corporation (NASDAQ: YELL) – GlobalTranz has awarded two 2020 Carrier of the Year honors to Yellow companies: YRC Freight, Cross-Border LTL and Reddaway, Western Regional LTL. GlobalTranz, a technology company providing award-winning cloud-based multi-modal transportation management system products to shippers, carriers, 3PLs and brokers, presented its carrier awards based on financial performance, technological innovation, collaboration, customer service, growth and overall excellence. “It’s pretty incredible for a leading logistics provider to recognize the Company’s customer service and financial performance in 2020, one of the most challenging business climates,” said Jason Bergman, Chief Commercial Officer. “A huge ‘congratulations’ for the Carrier of the Year, Cross-Border LTL and Carrier of the Year, Western Regional LTL go out to the YRC Freight and Reddaway employees whose dedication, hard work and customer-obsessed focus on getting the job done are the reason we achieve such third-party recognition.” To learn more about Yellow and the capabilities across its super-regional network and five brands – YRC Freight, Reddaway, Holland, New Penn and HNRY Logistics – please visit https://www.myyellow.com. About Yellow CorporationYellow Corporation has one of the largest, most comprehensive logistics and less-than-truckload (LTL) networks in North America with local, regional, national, and international capabilities. Through our teams of experienced service professionals, Yellow Corporation offers industry-leading expertise in flexible supply chain solutions, ensuring customers can ship industrial, commercial, and retail goods with confidence. Yellow Corporation, headquartered in Overland Park, Kan., is the holding company for a portfolio of LTL brands including Holland, New Penn, Reddaway, and YRC Freight, as well as the logistics company HNRY Logistics. Please visit our website at www.myyellow.com for more information. Media Contacts:Mike Kelley913-696-6121mike.kelley@myellow.com Heather Nauertheather.nauert@myellow.com Investor Contact:Tony Carreño913-696-6108investor@myyellow.com
Efficacy Across Mydriatic Agents in Reversing Pharmacologically Induced Mydriasis Informed Phase 3 Registration MIRA-2 Study Design Topline Results for Phase 3 MIRA-2 Trial Expected in March 2021 FARMINGTON HILLS, Mich., March 05, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, announced that the results from the MIRA-1 (NCT04024891) Phase 2b clinical trial evaluating the safety and efficacy of Nyxol® in the reversal of mydriasis (dilation of pupil for eye exams) have been published in Optometry and Visual Science, the international, peer-reviewed journal of the American Academy of Optometry. The article will appear in the print edition and is available on-line at www.optvissci.com. “The continued peer-reviewed publications of our Nyxol clinical trial results allow us to highlight the iris dilator mechanism and emerging product profile of Nyxol. The findings of the MIRA-1 trial specifically demonstrate the potential of Nyxol to offer a safe and effective option for the reversal of mydriasis indication, for which there are presently no FDA approved therapies. The recently enrolled MIRA-2 Phase 3 pivotal trial leveraged the design and findings of the MIRA-1 Phase 2b trial,” said Mina Sooch, MBA, President and CEO of Ocuphire Pharma. The paper, titled “Phentolamine Eye Drops Reverse Pharmacologically Induced Mydriasis in a Randomized Phase 2b Trial”, reported the following key findings: In the Nyxol treatment group, 29% of subjects met with statistical significance return to within 0.2 mm of their baseline pupil diameter (PD) at 2 hours, compared with 13% in the placebo group. A significant difference was also seen at 4 hours and was independent of mydriatic agent.Nyxol eye drops demonstrated a significant improvement over placebo in reducing pupil diameter at 2 hours from the time of maximum pupil diameter, regardless of mydriatic agent. A significant improvement was also seen at 1, 4, and 6 hours.Treatment with Nyxol eye drops led to a reduction in time to return to baseline pupil diameter of nearly 2 hours when compared to placebo.When treated with Nyxol eye drops, 63% of subjects returned to their accommodative baseline 2 hours after tropicamide-induced mydriasis, a statistically significant increase relative to 38% of subjects treated with placebo.Nyxol eye drops demonstrated a favorable safety profile, with roughly one third of subjects experiencing mild conjunctival redness, but no other systemic or ocular adverse effects. Moreover, whether given Nyxol or placebo, any discomfort occurring after treatment was mild in intensity. “Many of my patients explain how frustrated they are by the lasting and disruptive effects of pupil dilation,” said Dr. Paul Karpecki O.D., Director of Cornea Services for the Kentucky Eye Institute. “The results from the MIRA-1 Phase 2b trial demonstrate that Nyxol continues to be a promising candidate that might offer a solution that could greatly improve the patient experience after dilated eye exams.” Highlights of this double-masked, randomized, placebo-controlled, multi-center Phase 2b clinical trial were presented at the 2020 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) by Dr. Paul Karpecki via video submission. For more information on the MIRA-1 trial design, refer to Clinicaltrials.gov NCT04024891. The MIRA-1 results informed the trial design of the Phase 3 MIRA-2 registration trial that recently completed recruitment. MIRA-2 is designed as a multi-center, randomized, double-masked, placebo-controlled, parallel, 24-hour Phase 3 trial that planned 168 healthy subjects, and ultimately enrolled 185 subjects. The primary efficacy endpoint for MIRA-2 is the percentage of subjects (study eyes) returning to within 0.2 mm of baseline pupil diameter at 90 minutes. Ophthalmic secondary efficacy endpoints include the percentage of subjects returning to baseline PD at other timepoints, mean change in pupil diameter from mydriatic maximum at multiple timepoints, and percent of subjects returning to baseline accommodation (with tropicamide). Efficacy endpoints will be analyzed at all timepoints and stratified by mydriatic agent and iris color. Safety assessments will include heart rate (HR), blood pressure (BP), conjunctival redness, and tolerability. For more information on the MIRA-2 trial design, refer to Clinicaltrials.gov NCT04620213. There are 3 noteworthy design differences between the MIRA-2 and MIRA-1 trials. First, the MIRA-1 trial was conducted only in dark irides, which are less responsive to both dilating agents and alpha-1 blocking agents (such as Nyxol). MIRA-2 enrolled an equal number of subjects with light and dark irides. Second, in MIRA-2, two drops of Nyxol were administered in the study eye compared to one drop of Nyxol in MIRA-1. Third, MIRA-2 is employing a 3:1:1 phenylephrine:tropicamide:paremyd randomization schema for mydriatic agents rather than 1:1 phenylephrine:tropicamide in MIRA-1. In MIRA-1, it was shown that phenylephrine-induced mydriasis reverses faster upon administration of Nyxol. Topline results for the Phase 3 MIRA-2 registration trial are expected in March 2021. About Pharmacologically Induced Mydriasis Every year in the U.S., approximately 100 million eye exams are performed that require dilation of the pupil (mydriasis) to examine the back of the eye either for routine check-ups, disease monitoring or surgical procedures. Depending on the individual and the color of their eyes, the pharmacologically-induced dilation can last anywhere from 6 to 24 hours. Dilated eyes have a heightened sensitivity to light and an inability to focus on near objects, causing difficulty with reading, working, and driving. Market research conducted by GlobalData surveyed several hundred patients and eye care providers (optometrists and ophthalmologists) about Reversal of Mydriasis (as well as Night Vision Disturbances and Presbyopia). Over 65% of surveyed patients reported moderate to severe negative impact of a dilated exam, underscoring the potential value of Nyxol’s role in improving comfort and daily function after pupil dilation. Additionally, an estimated 45% of patients responded that they would be very likely to request a dilation reversal drop, and more than 40% of eye care providers would be likely to use a reversal drop if such a treatment were commercially available. About Ocuphire Pharma Ocuphire is a publicly traded (NASDAQ: OCUP), clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire’s pipeline currently includes two small-molecule product candidates targeting front and back of the eye indications. The company’s lead product candidate, Nyxol® Eye Drops, is a once-daily preservative-free eye drop formulation of phentolamine mesylate, a non-selective alpha-1 and alpha-2 adrenergic antagonist designed to reduce pupil size, and is being developed for several indications, including dim light or night vision disturbances (NVD), reversal of pharmacologically-induced mydriasis (RM), and presbyopia, and has been studied in 7 Phase 1 and 2 trials. Ocuphire’s second product candidate, APX3330, is an oral tablet designed to inhibit angiogenesis and inflammation pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy (DR) and diabetic macular edema (DME), and has been studied in 11 Phase 1 and 2 trials. Nyxol is entering Phase 3 clinical development for NVD and RM, and Phase 2 for presbyopia. APX3330 is entering Phase 2 clinical development for DR/DME. As part of its strategy, Ocuphire will continue to explore opportunities to acquire additional ophthalmic assets and to seek strategic partners for late-stage development, regulatory preparation and commercialization of drugs in key global markets. Please visit www.clinicaltrials.gov to learn more about Ocuphire’s completed Phase 2 clinical trials and ongoing Phase 3 registration trials (NCT04620213 and NCT04638660), Phase 2 trial in presbyopia (NCT04675151) and soon to recruit Phase 2 trial in DR/DME (NCT04692688). For more information, please visit www.ocuphire.com. Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning Ocuphire’s product candidates, results of ongoing and future clinical trials, and commercialization and market opportunities. These forward-looking statements are based upon Ocuphire’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: (i) the success and timing of regulatory submissions and pre-clinical and clinical trials; (ii) regulatory requirements or developments; (iii) changes to clinical trial designs and regulatory pathways; (iv) changes in capital resource requirements; (v) risks related to the inability of Ocuphire to obtain sufficient additional capital to continue to advance its product candidates and its preclinical programs; (vi) legislative, regulatory, political and economic developments, (vii) changes in market opportunities, (viii) the effects of COVID-19 on clinical programs and business operations, and (ix) the success and timing of commercialization of any of Ocuphire’s product candidates. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors detailed in documents that have been and may be filed by Ocuphire from time to time with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ocuphire undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Ocuphire Contacts Mina Sooch, President & CEO Ocuphire Pharma, Inc. ir@ocuphire.comwww.ocuphire.com Corey Davis, Ph.D.LifeSci Advisorscdavis@lifesciadvisors.com
Detective Chief Constable Mark Roberts says assistance provided to identify abusers has been poor.
Rosa Woods - Pool/Getty ImagesMeghan Markle has said she was not allowed to make her own choices when she was a member of the royal family.The comments were made in a new preview clip from Oprah Winfrey’s eagerly-awaited interview with Meghan Markle and Prince Harry, which dropped Friday morning on CBS This Morning.In the new clip, Meghan said that she had not been “allowed” to give an interview before.In the clip, Oprah told Meghan that she recalled calling her before her wedding and asking for an interview.Meghan said: “I recall that conversation very well. I wasn’t even allowed to have that conversation with you personally. Right? There had to be people from the [communications team] sitting there…”Oprah then said: “You turned me down nicely…What is right about this time?”Meghan replied: “Well, so many things. That we are on the other side of a lot of life experience that’s happened. And also that we have the ability to make our own choices in way that I couldn’t have said yes to you then. That wasn’t my choice to make. So, as an adult who lived a really independent life, to then go into this construct, that is, um, different, than I think what people imagine it to be, it’s really liberating to be able to have the right and the privilege in some ways to be able to say, ‘Yes, I am ready to talk.’ To say it for yourself…. To be able to just make a choice on your own, to be able to speak for yourself.”Meghan’s new comments appear to reiterate a frequent complaint of hers that she was denied her voice and agency when she was a member of the royal family.The new clip came as tensions between Meghan and Harry and Buckingham Palace boiled over into all-out war, with reports in the British media suggesting multiple witnesses were ready to come forward and give evidence to a hastily-announced inquiry into alleged bullying by Meghan of her staff at Buckingham Palace.Meghan’s friends responded to the bullying claims by launching a social media fightback against Buckingham Palace today calling her a “warm, kind, caring person.”In a previous clip Meghan accused the palace of “perpetuating falsehoods” about them.An emotional Meghan said: “I don’t know how they could expect that after all of this time we would still just be silent if there is an active role that The Firm is playing in perpetuating falsehoods about us.”Read more at The Daily Beast.Get our top stories in your inbox every day. Sign up now!Daily Beast Membership: Beast Inside goes deeper on the stories that matter to you. Learn more.
MIAMI and TORONTO, March 5, 2021 /CNW/ - XTM, Inc. ("XTM" or the "Company") (QB: XTMIF) (CSE: PAID) (FSE: 7XT), a Miami and Toronto-based Fintech company in the neo-banking space, providing mobile banking and payment solutions around the world, is pleased to announce that its common shares are now trading on the OTCQB Venture Market (the "OTCQB Venture"), a US trading platform that is operated by the OTC Markets Group in New York.
Rise in demand for sportswear and protective wear and growing popularity of cooling fabrics drive fabulous demand for manufacturers fuel the global cooling fabrics market. Based on application, the sports apparel segment accounted for the largest market share in 2019 and would lead throughout the forecast period. Moreover, based on region, the market across North America held the highest market share in 2019 and would rule the roost by 2027.Portland, OR, March 05, 2021 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global cooling fabrics market generated $1.9 billion in 2019, and is projected to garner $3.2 billion by 2027, manifesting a CAGR of 8.6% from 2020 to 2027. The report provides a detailed analysis of changing market dynamics, key segments, major investment pockets, competitive landscape, value chain, and regional scenario. Rise in demand for sportswear and protective wear and growing popularity of cooling fabrics drive the global cooling fabrics market. However, high cost of product restrains the market growth. Contrarily, growth in demand for medical and defense applications create new opportunities in the next few years. Download PDF Brochure: https://www.alliedmarketresearch.com/request-sample/10659 Covid-19 Scenario: Manufacturing activities of cooling fabrics have been slowed down due to lockdown. In addition, the supply chain was also disrupted to curb the spread of coronavirus.The demand for cooling fabrics witnessed a sudden decline due to stoppage of manufacturing activities. However, the demand is expected to surge gradually as the industry is revitalizing. The global market is segmented on the basis of type, textile type, applications, and region. By textile type, the knitted segment accounted for the highest share, holding more than two-fifths of the total market share in 2019, and is projected to maintain its leadership status throughout the forecast period. On the other hand, the woven segment would witness the fastest CAGR of 9.2% from 2020 to 2027. Get Detailed COVID-19 Impact Analysis on the Cooling Fabrics Market @ https://www.alliedmarketresearch.com/request-for-customization/10659?reqfor=covid By application, the sports apparel segment accounted for the largest market share in 2019, contributing to more than half of the global cooling fabrics market, and is projected to maintain its dominant share in terms of revenue during the forecast period. On the other hand, the lifestyle segment is estimated to witness the fastest CAGR of 9.1% from 2020 to 2027. By region, North America generated the highest market share in 2019, holding more than two-fifths of the total market share, and is projected to maintain its lead position by 2027. On the other hand, the Asia-Pacific region is projected to witness the highest CAGR of 9.2% during the forecast period. The report also analyzes regions including Europe, and LAMEA. Leading players of the global cooling fabrics market analyzed in the research include Ahlstrom-Munksjö, Asahi Kasei Corporation, Burlington, Coolcore LLC, Formosa Taffeta Co., Ltd., Hexarmor, Nan Ya Plastics Corporation, Nilit, Polartec, and Tex-Ray Industrial Co., Ltd. Interested in Procuring this Report? Visit Here: https://www.alliedmarketresearch.com/cooling-fabrics-market/purchase-options Avenue Basic Plan | Library Access | 1 Year Subscription | Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at $699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan. Avenue Library Subscription | Request for 14 days free trial of before buying: https://www.alliedmarketresearch.com/avenue/trial/starter Get more information: https://www.alliedmarketresearch.com/library-access About Us: Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP, based in Portland, Oregon. AMR provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain. AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports. CONTACT: Contact: David Correa 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States Toll Free: 1-800-792-5285 UK: +44-845-528-1300 Hong Kong: +852-301-84916 India (Pune): +91-20-66346060 Fax: +1-855-550-5975 help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com
More than a quarter of lawmakers worldwide are women after the proportion inched higher in 2020, but progress is so slow that it will take 50 years at the present rate before they achieve parity with men, a global body of legislatures said on Friday. "Although progress has been steady over the past few years, it is still excruciatingly slow," the Inter-Parliamentary Union, made up of 179 national member parliaments and 13 regional parliaments, said in an annual 'Women in Parliament' report. "At the current rate, it will take another 50 years before gender parity is achieved in parliaments worldwide," the Geneva-based IPU said.
Philip underwent a successful procedure at St Bartholomew’s – just three months before his 100th birthday.
Of all the IPOs and SPACs that have debuted in the last six months, though, I think Unity Software (NYSE: U) is the one to focus on for the long haul. Revenue increased 43% from 2019 to $772.4 million, and free cash flow was negative $20.2 million (although it turned free-cash-flow positive in the fourth quarter, generating $3.6 million).
Kenneth Shiels’ squad had edged out Wales on head-to-head away goals in Group C.
The economy added 379,000 jobs in February and unemployment fell to 6.2%
As the coronavirus crisis drags on, Americans are desperate for financial relief -- and the $1.9 trillion stimulus proposal in the works could help. On Thursday, March 4, the Senate took its first big step toward passing its relief bill. In fact, Senate Majority Leader Chuck Schumer said the Senate will stay in session to finish up the bill this week.
The Chief of the Defence Staff, General Sir Nick Carter, will stay on to oversee the implementation of the changes.
Equity Residential (NYSE: EQR) today provided an update regarding certain same store Residential operating trends in its business.